Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Mol Cancer Ther. 2019 Sep 5;18(11):1916–1925. doi: 10.1158/1535-7163.MCT-18-1334

Figure 3: Effect of RX-5902 on nuclear β-catenin and downstream effector proteins.

Figure 3:

(A) MDA-MB-231, CAL-120, MDA-MB-436 and MCF-10A cells were treated with RX-5902 100 nM for 24 hours and immunoblotting was performed for MCL-1, phosphorylated p68, p68 and actin. Additionally, nuclear and cytoplasmic extract isolation was performed. Immunoblotting was performed for β-catenin and actin. (B) Quantification of immunoblots for nuclear β-catenin and MCL-1 normalized to actin and no drug control. (C) TNBC cell lines sensitive to RX-5902 (Cal-51, HCC-1806 and MDA-MB-468) were treated with RX-5902 and immunoblotting was performed for MCL-1 and actin. (D) Quantification of immunoblots for MCL-1. *p<0.05, ****p<0.0001.